Snapshot from Aug 15, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Smith+Nephew gets FDA De Novo for TESSA
Regulatory regulatory approval

Smith+Nephew gets FDA De Novo for TESSA

Analysis based on 8 articles · First reported Jul 29, 2026 · Last updated Jul 29, 2026

Sentiment
40
Attention
3
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The FDA De Novo classification opens a new regulatory category and positions Smith+Nephew as a leader in digital sports medicine, potentially boosting its competitive edge and revenue growth. The positive sentiment may lift Smith+Nephew's stock price in the near term.

Medical Devices Sports Medicine Orthopedics
Event Summary

Smith+Nephew announced that the U.S. United States — Food and Drug Administration (FDA) granted De Novo classification for its TESSA Spatial Surgery System, a device that uses AI, augmented reality, and cloud computing to assist in arthroscopic procedures, starting with ACL reconstruction. The system, which originated from Perceive3D S.A. (acquired by Smith+Nephew), creates patient-specific 3D models from preoperative scans and overlays them onto live video. This classification establishes a new FDA category for intra-articular orthopedic stereotaxic navigation instruments. Commercial introduction is planned for Q3 2026 with broader deployment in 2027.

Key Actions
100 United States — Food and Drug Administration granted De Novo classification Smith & Nephew
70 Smith & Nephew will commercially introduce
60 Smith & Nephew acquired Perceive3D S.A.
Entities Involved
stock
Smith & Nephew
Smith+Nephew received FDA De Novo classification for its TESSA system, reinforcing its leadership in digital sports medicine and potentially driving future revenue.
Importance 100.0 Sentiment 60.0
govactor
United States — Food and Drug Administration
The FDA granted De Novo classification, creating a new regulatory category for intra-articular orthopedic stereotaxic navigation instruments.
Importance 80.0 Sentiment 0.0
priv
Perceive3D S.A.
Perceive3D S.A., a spin-off from the University of Coimbra, was acquired by Smith+Nephew and its technology forms the basis of the TESSA system.
Importance 30.0 Sentiment 0.0
subs
Amazon — Amazon Web Services
AWS provides cloud infrastructure for the TESSA system's deep-learning algorithms.
Importance 20.0 Sentiment 0.0
stock
Nvidia
NVIDIA AI infrastructure powers the TESSA system's real-time video overlay.
Importance 20.0 Sentiment 0.0
per
Scott Schaffner
President of Global Sports Medicine at Smith+Nephew, announced the system's commercial introduction.
Importance 20.0 Sentiment 0.0
per
Jorge Chahla
Orthopedic surgeon who commented on the TESSA system's role in supporting surgical planning.
Importance 10.0 Sentiment 0.0
per
Anil Ranawat
Chief of Hip and Knee Division at Hospital for Special Surgery, endorsed the system for ACL surgery.
Importance 10.0 Sentiment 0.0
index
FTSE 100 Index
Smith+Nephew is a constituent of the FTSE 100, but the event has minimal direct impact on the index.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Nvidia
Amazon — Amazon Web Services related ↔ Nvidia
Nvidia related ↔ FTSE 100 Index
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.